Jury selection to start in Novartis discrimination trial; Court upholds Teva's patent on Seasonique;

@FiercePharma: Pharma layoffs plunge to just 308 in March. Report | Follow @FiercePharma

> Askapatient.com visitors reported Fosamax effects years before medical lit. Story

> Jury selection is set to begin Wednesday for a major class-action trial over claims that drug giant Novartis discriminates against its female sales force, with managers allegedly telling women workers not to get pregnant. Item

> A U.S. federal court upheld a patent for Teva Pharmaceutical Industries' Seasonique birth-control pill in a case against generic drugmaker Watson Pharmaceuticals. Release | Report

> Under an amendment to its Actonel agreement with Sanofi-Aventis, Warner Chilcott will take over promotion, marketing and R&D decisions and costs in the U.S. and Puerto Rico; previously, Warner shared those costs with Sanofi. Warner Chilcott release

> Allergan, broadening its urology product line, says it has reached a deal with Serenity Pharmaceuticals to develop and sell the privately held company's drug now in late-stage testing to treat frequent night-time urination. Report

> AstraZeneca Pharma India has entered the Indian anti-diabetes drug market by joining hands with Bristol-Myers Squibb India for developing and commercializing two compounds for the treatment of Type 2 diabetes. Report

> An Australian medical researcher claims Wyeth duped him into publishing a scientific paper that became part of its campaign to play down the dangers of its drugs for menopausal women, The Australian writes. Report

Biotech News

 @FierceBiotech: Two high-profile biotech CEOs assess impact of reform bill. Report | Follow @FierceBiotech

 @JohnCFierce: According to Repros' last quarterly report, it ended 09 with $1.9M in cash and its third annual going concern warning. | Follow @JohnCFierce

> Selecta Biosciences wasn't out looking for money--but it found them nevertheless. Just a little more than a year after hauling in a $15.1 million Series B round, the developer has raised a similar amount from some top-level biotech backers, with OrbiMed Advisers stepping in to lead. Report

> Accelrys and Symyx join R&D forces in merger deal. Article

> Repros shares rally on move to get FDA clinical hold lifted. Item

> Glaucoma drug focus inspires $20 million A round for Altheos. Report

> Keryx shares spike as cancer drug wins fast track. Story

> FDA staffers question Daxas' safety, benefits and suicides as review looms. Report

Biotech IT News

> CROs in France, Germany adopt Oracle systems. Article

> Pfizer 3.0 taps EHRs, mobile tech for drug safety. Pfizer news

> Explorys to tap anonymized EHR data for clinical collaborations. Report

And Finally... Thalidomide, a drug that caused birth defects when it was launched as a morning sickness pill half a century ago, may be useful for treating a hereditary condition that affects blood vessels. Report

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.